explore -WSS

explore

author：knowledge 2025-09-29 21:13:34 - browse：8

Adam's take main illustration — Molly Ferguson/STAT

For two days starting on Sunday, Moonlake Immunotherapeutics happily crunched numbers and shared results from a mid-stage clinical trial that depicted its experimental antibody in the most flattering terms possible.

The drug, called sonelokimab, was “changing the game” for the treatment of a debilitating skin condition called hidradenitis suppurativa, or HS, said Moonlake CEO Jorge Santos da Silva, on a call for investors and analysts. The drug’s benefit for patients placed it “at the top of the heap,” he added.

For other, equally important data from the same study that did not fit Moonlake’s home-run narrative, the company took a DIY approach. Curious about how sonelokimab performed against a treatment that’s already approved for HS? Pull out a calculator and do the math yourself. How badly did a higher dose of the drug underperform a lower dose? Take a guess.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Readout LOUD podcast: Live from STAT Breakthrough Summit West

WSS

Addiction experts warn against a second 'war on drugs'

Criminal prosecution for violating HIPAA: an emerging threat

STAT Boddities: What happens to the brain when we get scared?

Helping hospitals and community health centers plan for resilience

Congress might make insulin pumps more accessible to the blind

Big Tobacco's 'harm reduction': Is it for real, or a sham?

focus

explore

hotspot

Alkermes shareholders re

Readout LOUD podcast: Live from STAT Breakthrough Summit West

Virginia high school admissions case could be legal follow

With measles on the rise, a personal story of a devastating disease

BioMarin wins approval for gene therapy to treat hemophilia A

Readers respond to H5N1 and livestock movements, and more

Peter Hotez and the public health issue of online harassment

Why Eli Lilly’s earnings didn’t quite live up to the hype

Hepatitis C has a cure — but many Americans still lack access to it

Sick patients collapsed waiting for care at Massachusetts hospital with known safety violations

knowledge

Abbott's new heart device gets FDA advisory panel nod

Case highlights the risks of experimental stem cell therapy

Bernie Sanders gets little from pharma CEOs on drug prices

Readers respond to H5N1 and livestock movements, and more

Microsoft's Peter Lee says ChatGPT shouldn't be used for initial diagnosis

Here’s what’s in the FDA plan to include pregnant women in clinical trials

leisure time

focus

entertainment

hotspot